Department of Anesthesiology and Pain Medicine, School of Medicine, Daegu Catholic University, Daegu, Republic of Korea.
Department of Anesthesiology and Pain Medicine, Yeungnam University College of Medicine, Daegu, Republic of Korea.
Medicine (Baltimore). 2023 Dec 29;102(52):e36824. doi: 10.1097/MD.0000000000036824.
A multimodal therapeutic strategy for preventing postoperative nausea and vomiting (PONV) benefits moderate- and high-risk surgical patients. We compared the efficacy of a combination of midazolam and ramosetron and a combination of midazolam and palonosetron for PONV prophylaxis in patients scheduled for laparoscopic cholecystectomy.
We enrolled 68 patients aged 20 to 65 years undergoing laparoscopic cholecystectomy. Patients were randomly allocated to the midazolam 0.05 mg/kg with ramosetron 0.3 mg (MR) or midazolam 0.05 mg/kg with palonosetron 0.075 mg (MP) groups. The incidence of PONV, severity of nausea, use of rescue antiemetics, and pain severity were evaluated at 2, 24, and 48 hours after surgery.
The incidence (38.2% vs 5.9%) and severity of postoperative nausea were significantly lower in the MP group at 2 hours after surgery (P < .05). There were no significant differences in the incidence of vomiting, use of rescue antiemetics, or pain severity between the 2 groups.
The combination of midazolam with palonosetron significantly decreased the incidence and severity of postoperative nausea compared with midazolam combined with ramosetron, especially in the early postoperative phase (0-2 hours) in patients undergoing laparoscopic cholecystectomy.
多模式治疗策略预防术后恶心和呕吐(PONV)有益于中高危手术患者。我们比较了咪达唑仑联合雷莫司琼和咪达唑仑联合帕洛诺司琼预防腹腔镜胆囊切除术患者 PONV 的疗效。
我们纳入了 68 名年龄在 20 岁至 65 岁之间的行腹腔镜胆囊切除术的患者。患者随机分为咪达唑仑 0.05mg/kg 联合雷莫司琼 0.3mg(MR)或咪达唑仑 0.05mg/kg 联合帕洛诺司琼 0.075mg(MP)组。在术后 2、24 和 48 小时评估 PONV 的发生率、恶心严重程度、使用解救性止吐药和疼痛严重程度。
与 MR 组相比,MP 组术后 2 小时 PONV 的发生率(38.2% vs. 5.9%)和恶心严重程度显著降低(P<0.05)。两组间呕吐的发生率、使用解救性止吐药和疼痛严重程度无显著差异。
与咪达唑仑联合雷莫司琼相比,咪达唑仑联合帕洛诺司琼显著降低了腹腔镜胆囊切除术患者术后恶心的发生率和严重程度,尤其是在术后早期(0-2 小时)。